Amgen, Inc. (NASDAQ:AMGN) Shares Bought by Sei Investments Co.

Sei Investments Co. boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 422,640 shares of the medical research company’s stock after acquiring an additional 24,460 shares during the period. Sei Investments Co.’s holdings in Amgen were worth $101,854,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Amgen by 3.4% during the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after buying an additional 1,585,911 shares during the last quarter. State Street Corp lifted its position in shares of Amgen by 0.9% during the 4th quarter. State Street Corp now owns 26,226,343 shares of the medical research company’s stock worth $6,322,385,000 after buying an additional 236,791 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Amgen by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,385,368 shares of the medical research company’s stock worth $575,041,000 after buying an additional 10,043 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Amgen by 7.0% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,353,360 shares of the medical research company’s stock worth $455,399,000 after buying an additional 154,094 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in shares of Amgen by 21.2% during the 3rd quarter. California Public Employees Retirement System now owns 1,567,552 shares of the medical research company’s stock worth $303,337,000 after buying an additional 274,146 shares during the last quarter. Institutional investors and hedge funds own 76.69% of the company’s stock.

AMGN traded up $0.44 during trading on Friday, hitting $223.48. The stock had a trading volume of 1,611,948 shares, compared to its average volume of 2,409,702. The company has a debt-to-equity ratio of 2.79, a quick ratio of 1.16 and a current ratio of 1.44. The firm has a market capitalization of $135.13 billion, a P/E ratio of 17.36, a PEG ratio of 2.00 and a beta of 1.12. The company’s 50-day moving average price is $233.82 and its 200 day moving average price is $215.60. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $244.99.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $3.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.47 by $0.17. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The business had revenue of $6.20 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the prior year, the company posted $3.42 EPS. The business’s revenue for the quarter was down .5% on a year-over-year basis. As a group, equities analysts expect that Amgen, Inc. will post 15.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.60 per share. The ex-dividend date is Thursday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.86%. Amgen’s dividend payout ratio is 39.14%.

In other news, SVP David Piacquad sold 9,264 shares of the company’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $229.93, for a total transaction of $2,130,071.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 9,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total transaction of $2,074,860.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,426 shares of company stock worth $6,351,866. Corporate insiders own 0.25% of the company’s stock.

Several brokerages have recently weighed in on AMGN. Oppenheimer boosted their price objective on shares of Amgen from to in a research report on Tuesday, January 21st. Cfra boosted their price objective on shares of Amgen from $215.00 to $223.00 and gave the stock a “hold” rating in a research report on Friday, January 31st. Cantor Fitzgerald restated a “buy” rating and set a $255.00 price objective on shares of Amgen in a research report on Tuesday, January 14th. Argus restated a “buy” rating and set a price objective on shares of Amgen in a research report on Thursday, February 6th. Finally, Leerink Swann upped their price target on shares of Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Amgen currently has a consensus rating of “Hold” and a consensus price target of $237.33.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Bid-Ask Spread

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.